Tranexamic acid drug used to control blood loss in major surgery in orthopedics like total knee replacement.

Effect of Tranexamic acid on peri operative blood loss in Primary Total Knee Replacement - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/08/072959

Enrollment

Registered

2024-08-23

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissue

Interventions

Intervention1: Intravenous administration of Tranexamic acid: Intravenous administration of Tranexamic acid 30 minutes before the incision is used to control or prevent heavy or excessive bleeding aft

Eligibility

Inclusion criteria

Inclusion criteria: Patient undergoing primary Total knee replacement due to osteoarthritis or rheumatoid arthritis.

Exclusion criteria

Exclusion criteria: 1)Allergies to drugs used 2)Changes related to coagulation profile 3)Use of Antiplatelet drugs seven days before surgery 4)Kidney or Liver disease 5)Previous history of deep venous thrombosis or pulmonary embolism

Design outcomes

Primary

Measure	Time frame
At the end of study their might be less blood loss in patient manage with intravenous tranexamic acid compare to patient manage with peri articular infiltration of tranexamic acid in posterior aspect of capsule.Timepoint: Assessment will be done at 12 months.	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactSHARAD SAWANT

Datta Meghe Institute of Higher Education And Research Sawangi Meghe

svd1111@gmail.com9860452519

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026